Literature DB >> 11295109

High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression.

A Wellmann1, P Flemming, P Behrens, K Wuppermann, H Lang, K Oldhafer, I Pastan, U Brinkmann.   

Abstract

The CSE1L/CAS protein (CAS) is a Ran-binding protein with a function as nuclear transport (export) factor. Like recently observed for ran and other ran-binding proteins, CSE1L/CAS simultaneously plays a role in the mitotic spindle checkpoint, which assures genomic stability during cell division. This checkpoint is frequently disturbed in neoplasias of various origin, including hepatic tumors. We have evaluated by immunohistology the expression of CAS in adult and embryonic liver, hepatitis, and in liver hyperplasias. Normal hepatocytes revealed no CAS expression while embryonic liver showed strong expression in all parenchymal cells. Bile ducts stained positive with anti-CAS antibodies, and strong CAS expression was also detected at the interface between bile ducts and hepatocytes under conditions associated with regenerative proliferation. The localization of these CAS expressing cells correlated with the distribution of putative liver stem-cells. In active viral (but not in inactive) hepatitis, strong hepatocytal CAS expression correlates in site and intensity with degree of inflammation. Neoplastic liver demonstrated different degrees of CAS expression: no remarkable expression in adenomas, moderate expression in a narrow rim of hepatocytes and in periseptal cholangiolar proliferations in focal nodular hyperplasia, and strong CAS expression in hepatocellular carcinoma. Less differentiated tumors stain stronger than well differentiated. Cholangio-cellular carcinomas show even stronger CAS expression than hepatocellular carcinomas. Our observation of strong expression of CAS in liver cells that are committed for proliferation among them possibly liver stem cells, and in liver neoplasms, is consistant with the fact that CAS functions not solely as a nuclear transport factor but that it is also essential for cell proliferation, particularly for the mitotic spindle checkpoint. Interestingly, genomic instability is frequently observed in hepatic tumors which we have shown here to express large amounts of CAS. Since the degree of CAS-expression correlates with the grade of tumor dedifferentiation, we suggest that CAS should also be further investigated as prognostic marker for hepatic neoplasms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295109     DOI: 10.3892/ijmm.7.5.489

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  15 in total

Review 1.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

2.  CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression.

Authors:  Anke H Sillars-Hardebol; Beatriz Carvalho; Jeroen A M Beliën; Meike de Wit; Pien M Delis-van Diemen; Marianne Tijssen; Mark A van de Wiel; Fredrik Pontén; Gerrit A Meijer; Remond J A Fijneman
Journal:  Cell Oncol (Dordr)       Date:  2012-06-19       Impact factor: 6.730

Review 3.  The prognostic molecular markers in hepatocellular carcinoma.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

Review 4.  Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.

Authors:  Cheng-Jeng Tai; Chung-Huei Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2010-08-11

5.  Roles of the CSE1L-mediated nuclear import pathway in epigenetic silencing.

Authors:  Qiang Dong; Xiang Li; Cheng-Zhi Wang; Shaohua Xu; Gang Yuan; Wei Shao; Baodong Liu; Yong Zheng; Hailin Wang; Xiaoguang Lei; Zhuqiang Zhang; Bing Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-10       Impact factor: 11.205

6.  The Cellular Apoptosis Susceptibility Protein (CAS) Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis and Cell Proliferation.

Authors:  Prashant Monian; Xuejun Jiang
Journal:  J Biol Chem       Date:  2015-12-14       Impact factor: 5.157

7.  CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cells.

Authors:  Shunta Nagashima; Junichi Maruyama; Kaori Honda; Yasumitsu Kondoh; Hiroyuki Osada; Makiko Nawa; Ken-Ichi Nakahama; Mari Ishigami-Yuasa; Hiroyuki Kagechika; Haruhiko Sugimura; Hiroaki Iwasa; Kyoko Arimoto-Matsuzaki; Hiroshi Nishina; Yutaka Hata
Journal:  J Biol Chem       Date:  2021-05-20       Impact factor: 5.157

8.  Cellular apoptosis susceptibility (CAS) is linked to integrin β1 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC).

Authors:  Juliane Winkler; Stephanie Roessler; Carsten Sticht; Amanda L DiGuilio; Elisabeth Drucker; Kerstin Holzer; Eva Eiteneuer; Esther Herpel; Kai Breuhahn; Norbert Gretz; Peter Schirmacher; Alessandro Ori; Stephan Singer
Journal:  Oncotarget       Date:  2016-04-19

9.  CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells.

Authors:  Ching-Fong Liao; Shue-Fen Luo; Li-Tzu Li; Chuang-Yu Lin; Ying-Chun Chen; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2008-07-03

Review 10.  Targeting nucleocytoplasmic transport in cancer therapy.

Authors:  Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link
Journal:  Oncotarget       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.